DE69528523T2 - Rezeptor modulierendes mitteln und entsprechendes verfahren - Google Patents

Rezeptor modulierendes mitteln und entsprechendes verfahren

Info

Publication number
DE69528523T2
DE69528523T2 DE69528523T DE69528523T DE69528523T2 DE 69528523 T2 DE69528523 T2 DE 69528523T2 DE 69528523 T DE69528523 T DE 69528523T DE 69528523 T DE69528523 T DE 69528523T DE 69528523 T2 DE69528523 T2 DE 69528523T2
Authority
DE
Germany
Prior art keywords
receptor modulating
corresponding method
modulating agent
receptor
vitamin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69528523T
Other languages
English (en)
Other versions
DE69528523D1 (de
Inventor
A Charles Morgan
D Scott Wilbur
Pradip M Pathare
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
KYTO BIOPHARMA, INC., WEST PALM BEACH, FLA., US
University of Washington
Original Assignee
University of Washington
Receptagen Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/406,194 external-priority patent/US5869465A/en
Priority claimed from US08/406,192 external-priority patent/US5739287A/en
Priority claimed from US08/406,191 external-priority patent/US5840880A/en
Application filed by University of Washington, Receptagen Corp filed Critical University of Washington
Application granted granted Critical
Publication of DE69528523D1 publication Critical patent/DE69528523D1/de
Publication of DE69528523T2 publication Critical patent/DE69528523T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H23/00—Compounds containing boron, silicon, or a metal, e.g. chelates, vitamin B12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/82—Proteins from microorganisms
    • Y10S530/825—Bacteria
DE69528523T 1994-04-08 1995-04-07 Rezeptor modulierendes mitteln und entsprechendes verfahren Expired - Lifetime DE69528523T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US22483194A 1994-04-08 1994-04-08
US08/406,194 US5869465A (en) 1994-04-08 1995-03-16 Methods of receptor modulation and uses therefor
US08/406,192 US5739287A (en) 1994-04-08 1995-03-16 Biotinylated cobalamins
US08/406,191 US5840880A (en) 1994-04-08 1995-03-16 Receptor modulating agents
PCT/US1995/004404 WO1995027723A1 (en) 1994-04-08 1995-04-07 Receptor modulating agents and methods relating thereto

Publications (2)

Publication Number Publication Date
DE69528523D1 DE69528523D1 (de) 2002-11-14
DE69528523T2 true DE69528523T2 (de) 2003-06-12

Family

ID=27499380

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69528523T Expired - Lifetime DE69528523T2 (de) 1994-04-08 1995-04-07 Rezeptor modulierendes mitteln und entsprechendes verfahren

Country Status (9)

Country Link
US (2) US5840712A (de)
EP (1) EP0754189B1 (de)
JP (1) JPH10502334A (de)
KR (1) KR100361075B1 (de)
AT (1) ATE225799T1 (de)
AU (1) AU2283595A (de)
CA (1) CA2187346C (de)
DE (1) DE69528523T2 (de)
WO (1) WO1995027723A1 (de)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1015475A1 (de) * 1995-10-19 2000-07-05 Receptagen Corporation Wirkstoffe zur modulation von vitaminen b12? -rezeptoren
US5739313A (en) * 1995-11-13 1998-04-14 Regents Of The University Of Minnesota Radionuclide labeling of vitamin B12 and coenzymes thereof
US20010023288A1 (en) * 1999-07-07 2001-09-20 Wilbur D. Scott Trifunctional reagent for conjugation to a biomolecule
JP2001501596A (ja) 1996-08-27 2001-02-06 ユニバーシティ・オブ・ユタ・リサーチ・ファウンデーション バイオコンジュゲートおよび生物学的活性剤の送達
AU2003204343B2 (en) * 1998-06-12 2007-03-15 Access Pharmaceuticals Australia Pty Limited Vitamin B12 derivatives and methods for their preparation
AUPP405098A0 (en) * 1998-06-12 1998-07-02 Access Pharmaceuticals Australia Pty Limited Novel methods of preparation of vitamin b12 derivatives suitable for conjugation to pharmaceuticals
AU8366398A (en) * 1998-07-07 2000-01-24 Department Of Radiation Oncology University Of Washington Trifunctional reagent for conjugation to a biomolecule
WO2000011479A1 (en) * 1998-08-20 2000-03-02 Axis-Shield Asa Assay method for cardiovascular disease
US6806363B1 (en) * 1999-04-16 2004-10-19 Mayo Foundation For Medical Education & Research Cobalamin conjugates useful as antitumor agents
AUPQ071299A0 (en) * 1999-06-02 1999-06-24 Access Pharmaceuticals Australia Pty Limited Vitamin directed dual targeting therapy
JP2003512338A (ja) * 1999-10-15 2003-04-02 メイオウ・フアウンデーシヨン・フオー・メデイカル・エジユケイシヨン・アンド・リサーチ 造影剤および抗腫瘍薬として有用なコバラミン結合体
CA2387767A1 (en) 1999-10-15 2001-04-26 Henricus P. C. Hogenkamp Cobalamin conjugates useful as imaging and therapeutic agents
US7591995B2 (en) 1999-10-15 2009-09-22 Mayo Foundation For Medical Education And Research Cobalamin conjugates useful as imaging and therapeutic agents
CA2387503C (en) * 1999-10-26 2010-02-09 University Of Utah Research Foundation Fluorescent cobalamins and uses thereof
US6797521B2 (en) 1999-10-26 2004-09-28 University Of Utah Research Foundation Fluorescent cobalamins and uses thereof
US7183392B2 (en) 2000-03-27 2007-02-27 Zyomyx, Inc. Site-specific, covalent bioconjugation of proteins
JP5102928B2 (ja) 2000-06-30 2012-12-19 イーライ リリー アンド カンパニー 新規な葉酸代謝拮抗薬の組み合わせ療法
WO2002042427A2 (en) * 2000-10-25 2002-05-30 Surromed, Inc. Mass tags for quantitative analysis
EP1334114A2 (de) * 2000-10-25 2003-08-13 Mayo Foundation For Medical Education And Research Transcobalamin-bindende konjugate zur behandlung abnormaler zellulärer proliferation
NZ528714A (en) * 2001-03-16 2005-07-29 Univ Utah Res Found Fluorescent cobalamins and uses thereof to detect cancerous cells
JP2005514322A (ja) * 2001-05-15 2005-05-19 ページ ダブル フォーク 生体影響性成分と細胞標的化成分の所定の比を有する、実質的に均質な生体影響性物質、このような物質を作製するための方法、及びその使用法
US6752986B2 (en) * 2001-05-24 2004-06-22 The Cleveland Clinic Foundation Composition and methods for affecting metallocorrinoid uptake
JP2005508332A (ja) * 2001-09-28 2005-03-31 メイオウ・フアウンデーシヨン・フオー・メデイカル・エジユケイシヨン・アンド・リサーチ 薬剤を送達するための、輸送タンパク質とコンジュゲートコバラミンとの同時投与
US20040047917A1 (en) * 2002-09-06 2004-03-11 Stephen Wilson Drug delivery and targeting with vitamin B12 conjugates
WO2004073648A2 (en) * 2003-02-20 2004-09-02 The Cleveland Clinic Foundation Composition and methods for inhibiting cell survival
US7232805B2 (en) * 2003-09-10 2007-06-19 Inflabloc Pharmaceuticals, Inc. Cobalamin conjugates for anti-tumor therapy
AU2004303528B2 (en) 2003-12-22 2009-05-28 Paul Scherrer Institut Cobalamine derivatives useful for diagnosis and treatment of abnormal cellular proliferation
US7220842B2 (en) * 2004-04-05 2007-05-22 Dade Behring Inc. Immunoassays for buprenorphine and norbuprenorphine
CN101222853B (zh) * 2005-05-17 2012-07-18 卡吉尔公司 粒状卵磷脂、粒状溶血卵磷脂、它们的生产方法和包含它们的组合物
US8524454B2 (en) * 2006-04-07 2013-09-03 The Research Foundation Of State University Of New York Transcobalamin receptor polypeptides, nucleic acids, and modulators thereof, and related methods of use in modulating cell growth and treating cancer and cobalamin deficiency
US9044461B2 (en) 2006-04-07 2015-06-02 The Research Foundation Of State University Of New York Transcobalamin receptor polypeptides, nucleic acids, and modulators thereof, and related methods of use in modulating cell growth and treating cancer and cobalamin deficiency
US8575397B2 (en) * 2007-02-14 2013-11-05 Biocompatibles Uk Limited Derivatisation of biological molecules
CN101715342A (zh) * 2007-03-19 2010-05-26 因弗拉布洛克制药公司 钴胺素紫杉烷生物结合物
WO2011130716A2 (en) 2010-04-16 2011-10-20 Access Pharmaceuticals, Inc. A nanostructures containing vitamin b12 for facilitated delivery of drugs across biological barriers
KR20140026396A (ko) 2011-03-08 2014-03-05 어섹스 팔마큐티칼스 인코포레이티드 생물학적 막을 가로질러 활성물질의 전달을 위한 표적화된 나노담체 시스템
US9120858B2 (en) 2011-07-22 2015-09-01 The Research Foundation Of State University Of New York Antibodies to the B12-transcobalamin receptor

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4167556A (en) * 1977-06-02 1979-09-11 Yissum Research Development Company Of The Hebrew University Of Jerusalem Determination of transcobalamins
CA1180273A (en) * 1981-06-22 1985-01-02 Technicon Instruments Corporation Assay of vitamin b in12 xx
NZ217821A (en) * 1985-10-10 1989-07-27 Biotech Australia Pty Ltd Oral delivery system; complex of active agent and vitamin b12 or analogue thereof
CA1339491C (en) * 1988-09-26 1997-10-07 Say-Jong Law Nucleophilic polysubstituted aryl acridinium ester and uses thereof
US5241070A (en) * 1988-09-26 1993-08-31 Ciba Corning Diagnostics Corp. Nucleophilic polysubstituted aryl acridinium esters and uses thereof
US5196510A (en) * 1988-12-29 1993-03-23 Cytogen Corporation Molecular recognition units
DE3900648A1 (de) * 1989-01-11 1990-07-12 Boehringer Mannheim Gmbh Neue cobalamin-saeurehydrazide und davon abgeleitete cobalamin-konjugate
EP0425680A4 (en) * 1989-02-28 1992-07-08 Teijin Limited New vitamin b 12? derivative, production thereof, and application thereof
US5310656A (en) * 1989-06-26 1994-05-10 Tritech Partners Vitamin B12 assay
US5294536A (en) * 1992-04-23 1994-03-15 Pb Diagnostic Systems, Inc. Conjugates
JPH07508174A (ja) * 1992-05-08 1995-09-14 レセプタジェン　コーポレイション ビタミンｂ１２／トランスコバラミン２レセプターに対する抗−レセプター剤
DE4239815A1 (de) * 1992-11-26 1994-06-01 Boehringer Mannheim Gmbh Verbesserte B¶1¶¶2¶-Konjugate
US5548064A (en) * 1993-05-24 1996-08-20 Biotech Australia Pty Limited Vitamin B12 conjugates with EPO, analogues thereof and pharmaceutical compositions
US5739287A (en) * 1994-04-08 1998-04-14 University Of Washington Biotinylated cobalamins
US5574018A (en) * 1994-07-29 1996-11-12 Amgen Inc. Conjugates of vitamin B12 and proteins

Also Published As

Publication number Publication date
ATE225799T1 (de) 2002-10-15
JPH10502334A (ja) 1998-03-03
WO1995027723A1 (en) 1995-10-19
KR970702290A (ko) 1997-05-13
CA2187346C (en) 2010-06-29
EP0754189B1 (de) 2002-10-09
CA2187346A1 (en) 1995-10-19
KR100361075B1 (ko) 2003-04-10
AU2283595A (en) 1995-10-30
US5840712A (en) 1998-11-24
EP0754189A1 (de) 1997-01-22
US6083926A (en) 2000-07-04
DE69528523D1 (de) 2002-11-14

Similar Documents

Publication Publication Date Title
DE69528523T2 (de) Rezeptor modulierendes mitteln und entsprechendes verfahren
DE69616873D1 (de) Überbrückungsvorrichtung für Gelenkprothese
NO994998L (no) Fusjonsproteiner
ATE46084T1 (de) Immunotoxin-konjugate.
DE59610329D1 (de) Airblast-Zerstäuberdüse
AU4675499A (en) Novel therapeutic agents that modulate neurokinin receptors
BR9609738A (pt) Composições para aplicação de droga para estabilidade melhorada de esteróides
FI980862A0 (fi) Kiraalisia metyylifenyylioksatsolidinoneja
DE69840415D1 (de) Haemasterlin analoge
NO20012930D0 (no) Azatioprinsammensetninger for tykktarmsadministrering
BR9608328A (pt) Derivados de benzil piperidina como agentes farmacêuticos
FR2767526B1 (fr) Composes bi-aromatiques relies par un radical heteroethynylene et compositions pharmaceutiques et cosmetiques les contenant
DE69622826D1 (de) Einheit zum Zuführen von Zigarettenschichten
DE69725799D1 (de) Einheit zum Bilden von Zigarettengruppen
DE29504415U1 (de) Absperrung für Gleisbaustellen
DE69612960D1 (de) Kühlbare verbindung zum verbinden von rohrteilstücken
KR970001356A (ko) 접합고리 피리딘을 함유한 벤즈이미다졸 유도체
DE29613843U1 (de) Gelenk für Orthesen
DE29504755U1 (de) Einstellbares Gelenk für Kindersportwagen
DE29510890U1 (de) Aggregat zum Fördern von Kraftstoff
KR970004494U (ko) 용접 장치용 용접 팁
NO981188D0 (no) 5-HT3-reseptorantagonister for dyskinesi
SE9503551D0 (sv) Förpackning för beklädda svetselektroder
FI950634A (fi) Lisäaine myrkyllisten kaasujen neutraloimiseksi
FR2739590B1 (fr) Ensemble bon de livraison/livret

Legal Events

Date Code Title Description
8327 Change in the person/name/address of the patent owner

Owner name: KYTO BIOPHARMA, INC., WEST PALM BEACH, FLA., US

Owner name: UNIVERSITY OF WASHINGTON, SEATTLE, WASH., US

8364 No opposition during term of opposition